Q1 2025 EPS Estimates for Corcept Therapeutics Incorporated (NASDAQ:CORT) Boosted by Zacks Research

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Analysts at Zacks Research boosted their Q1 2025 earnings per share estimates for shares of Corcept Therapeutics in a research note issued on Wednesday, September 25th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings of $0.29 per share for the quarter, up from their prior estimate of $0.27. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.12 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2025 earnings at $0.32 EPS, Q3 2025 earnings at $0.37 EPS, Q4 2025 earnings at $0.45 EPS, FY2025 earnings at $1.43 EPS and Q1 2026 earnings at $0.46 EPS.

Corcept Therapeutics (NASDAQ:CORT) last released its quarterly earnings data on Monday, July 29th. The biotechnology company reported $0.32 earnings per share for the quarter, beating the consensus estimate of $0.23 by $0.09. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The company had revenue of $163.80 million for the quarter, compared to the consensus estimate of $155.14 million. During the same quarter last year, the business posted $0.25 EPS. Corcept Therapeutics’s revenue for the quarter was up 39.1% on a year-over-year basis.

CORT has been the subject of a number of other reports. HC Wainwright lifted their price objective on Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, July 30th. Canaccord Genuity Group restated a “buy” rating and issued a $38.00 price target on shares of Corcept Therapeutics in a research report on Tuesday, July 30th. Truist Financial reiterated a “buy” rating and set a $65.00 price objective on shares of Corcept Therapeutics in a research report on Monday, June 17th. Finally, Piper Sandler lifted their target price on shares of Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 18th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $53.75.

Corcept Therapeutics Stock Performance

Shares of NASDAQ CORT opened at $43.93 on Friday. The firm has a 50 day moving average price of $36.39 and a two-hundred day moving average price of $30.68. The stock has a market cap of $4.57 billion, a P/E ratio of 41.44 and a beta of 0.45. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $44.37.

Insider Activity at Corcept Therapeutics

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $32.81, for a total transaction of $72,182.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider William Guyer sold 10,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $35.30, for a total transaction of $353,000.00. Following the transaction, the insider now owns 6,039 shares of the company’s stock, valued at approximately $213,176.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Daniel N. Swisher, Jr. sold 2,200 shares of Corcept Therapeutics stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $32.81, for a total value of $72,182.00. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,451 shares of company stock valued at $1,090,844. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Norden Group LLC purchased a new position in Corcept Therapeutics during the 1st quarter valued at about $50,081,000. Norges Bank bought a new stake in Corcept Therapeutics during the 4th quarter worth approximately $24,603,000. Jacobs Levy Equity Management Inc. purchased a new stake in Corcept Therapeutics in the 1st quarter worth approximately $18,426,000. Jupiter Asset Management Ltd. boosted its holdings in Corcept Therapeutics by 1,149.0% in the 1st quarter. Jupiter Asset Management Ltd. now owns 744,469 shares of the biotechnology company’s stock valued at $18,753,000 after purchasing an additional 684,863 shares during the period. Finally, Clearbridge Investments LLC purchased a new position in shares of Corcept Therapeutics during the 1st quarter valued at $14,670,000. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.